M&A - MAXCYTE, INC.
Add to your watchlist
Upgrade to receive email alerts for new filings
Form Type: 8-K
Filing Date: 2025-01-30
Corporate Action: Acquisition
Type: New
Accession Number: 000155837025000526
Filing Summary: On January 30, 2025, MaxCyte, Inc. announced its acquisition of SeQure DX Inc., a leader in editing assessment services for cell and gene therapies. The press release detailing the acquisition was included as Exhibit 99.1. This acquisition is positioned to enhance MaxCyte's capabilities in the cell and gene therapy market, following their growth strategy as an emerging growth company under the Securities Act.
Additional details:
Press Release Date: 2025-01-30
Acquisition Target: SeQure DX Inc.
Business Focus: on-target and off-target editing assessment services for cell and gene therapies
Comments
No comments yet. Be the first to comment!